Multi-phase sponsored research agreement to evaluate Qymune's proprietary Q²TCE platform for a novel oncology program

Qymune Inc. (formerly QUM Therapeutics, Inc.), a biotechnology company developing next-generation T-cell engager therapeutics, today announced a research collaboration with Daiichi Sankyo (TSE: 4568) through its Daiichi Sankyo Research Institute San Diego to evaluate Qymune's proprietary Q²TCE platform technology for an undisclosed oncology target. Under the agreement, Qymune will conduct research activities over approximately 18 months across two phases to develop and characterize a T-cell engager candidate utilizing the Q²TCE platform. Financial terms were not disclosed.

"Collaborating with Daiichi Sankyo, one of the world's leading oncology companies, provides meaningful validation of our Q²TCE platform's differentiated approach to T-cell engagement," said Jaehak Oh, Ph.D., Chief Executive Officer of Qymune. "Our technology addresses a fundamental challenge in the T-cell engager field by achieving potent cytotoxicity while minimizing cytokine release – a balance that has limited many conventional approaches. We look forward to a productive scientific collaboration that leverages the complementary strengths of both companies."

About Qymune Inc.

Qymune Inc. (formerly QUM Therapeutics) is a San Francisco-based biotechnology company advancing next-generation T-cell engager therapeutics through its proprietary Q²TCE platform. The company's lead program, QUM1, is a CD19-targeting T-cell engager in development for autoimmune diseases and B-cell lymphoma. Qymune is backed by institutional investors and is headquartered in San Francisco, California.

About Q²TCE Technology

Qymune's Q²TCE platform represents a first-in-class approach to T-cell engagement with a proprietary target rather than the conventional T-cell engagers. This differentiated mechanism may enable a superior therapeutic index while significantly reducing cytokine release – a key driver of cytokine release syndrome (CRS) that has limited the clinical utility of many T-cell engager programs. The platform's proprietary antibody panel offers tunable binding affinities, enabling rapid pairing with diverse antibody targets across oncology and autoimmune disease applications.

Forward-Looking Statements

This announcement contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those anticipated. Qymune undertakes no obligation to update these statements.